Allostery Investments LP Purchases Shares of 479,100 KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Allostery Investments LP bought a new position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 479,100 shares of the specialty pharmaceutical company's stock, valued at approximately $4,058,000. KalVista Pharmaceuticals accounts for 4.2% of Allostery Investments LP's portfolio, making the stock its 6th largest position. Allostery Investments LP owned approximately 0.97% of KalVista Pharmaceuticals at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Boxer Capital Management LLC purchased a new position in KalVista Pharmaceuticals during the fourth quarter worth about $13,467,000. PDT Partners LLC raised its stake in shares of KalVista Pharmaceuticals by 56.8% during the 4th quarter. PDT Partners LLC now owns 35,201 shares of the specialty pharmaceutical company's stock worth $298,000 after buying an additional 12,747 shares in the last quarter. Aquatic Capital Management LLC acquired a new stake in shares of KalVista Pharmaceuticals in the 4th quarter valued at approximately $44,000. Susquehanna Fundamental Investments LLC purchased a new stake in shares of KalVista Pharmaceuticals in the fourth quarter valued at approximately $680,000. Finally, Nebula Research & Development LLC acquired a new position in KalVista Pharmaceuticals during the fourth quarter worth $98,000.

KalVista Pharmaceuticals Price Performance

KalVista Pharmaceuticals stock traded down $0.62 during mid-day trading on Tuesday, hitting $12.48. 651,726 shares of the company were exchanged, compared to its average volume of 411,917. KalVista Pharmaceuticals, Inc. has a 12-month low of $7.30 and a 12-month high of $15.50. The business's 50 day simple moving average is $11.95 and its two-hundred day simple moving average is $10.41. The company has a market capitalization of $620.65 million, a P/E ratio of -3.43 and a beta of 0.05.

Analysts Set New Price Targets

Several brokerages have commented on KALV. Jones Trading restated a "buy" rating and set a $30.00 target price on shares of KalVista Pharmaceuticals in a research report on Wednesday, March 26th. Citizens Jmp upgraded shares of KalVista Pharmaceuticals to a "strong-buy" rating in a research report on Friday, January 31st. TD Cowen initiated coverage on KalVista Pharmaceuticals in a report on Tuesday, January 7th. They issued a "buy" rating and a $30.00 price target on the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a report on Tuesday, April 8th. Finally, JMP Securities assumed coverage on KalVista Pharmaceuticals in a report on Friday, January 31st. They issued an "outperform" rating and a $19.00 target price on the stock. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $24.83.

Insider Buying and Selling

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 6,669 shares of the firm's stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $11.97, for a total value of $79,827.93. Following the sale, the chief executive officer now directly owns 287,811 shares of the company's stock, valued at approximately $3,445,097.67. This trade represents a 2.26 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Venrock Healthcare Capital Par acquired 100,000 shares of the company's stock in a transaction dated Wednesday, February 12th. The shares were bought at an average cost of $9.23 per share, with a total value of $923,000.00. Following the purchase, the insider now owns 5,217,285 shares in the company, valued at approximately $48,155,540.55. The trade was a 1.95 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 202,786 shares of company stock worth $1,880,511 and sold 17,292 shares worth $184,625. 10.50% of the stock is currently owned by company insiders.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).